CEO INVESTOR CONFERENCE February 13-14, 2017 • The Waldorf Astoria New York

bio.org/CEO • #BIOCEO16

bio.org/CEO • #BIOCEO17 CEO INVESTOR CONFERENCE

Now in its 19th year, the BIO CEO & Investor Conference WHY ATTEND? is one of the largest investor • EXPERIENCE the largest, unbiased forum where institutional conferences focused on investors, industry analysts, and senior biotechnology executives shape the future investment landscape of the industry. established and emerging publicly traded and select • HEAR Washington’s perspective on how the Trump Administration will address ACA, CMS and PDUFA VI. private biotech companies. • EVALUATE fresh investment opportunities including compatible, complementary and competitive companies.

• LEARN about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables.

• ATTEND fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2017.

• GAIN ACCESS to BIO’s One-on-One Partnering system for scouting potential investments and deal partners, optimizing your time at the event.

• HEAR presentations from more than 175 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences.

• GET THE PULSE of the current and proposed investment trends in biotechnology.

• NETWORK with peers, investors, and potential partners attending the conference and our exclusive receptions.

2 bio.org/CEO CEO INVESTOR CONFERENCE

2017 FIRESIDE CHAT SPEAKERS Fireside Chats feature candid discussions between biopharma executives, Wall Street analysts, and other high-level industry experts.

Hear about recent company Giovanni Caforio, MD Tony Coles, MD President and Chief Chairman and Chief successes, what keeps the Executive Officer, Executive Officer, C-suite up at night, and Bristol-Myers Squibb Yumanity Therapeutics where the industry’s leading companies are headed in 2017.

Jeffrey D. Marrazzo J. Joseph Kim, PhD Co-Founder and Chief President and Chief Executive Officer, Executive Officer, Spark Therapeutics Inovio Pharmaceuticals

Lynn Seely, MD Chief Executive Officer, Myovant Sciences

#BIOCEO17 3 2017 AGENDA

APPLYING MICROBIOME RESEARCH MODERATOR: Michael King, Managing Director and Senior TO THERAPEUTICS Research Analyst, JMP Securities Monday • February 13, 2017 • 9:00 am – 9:55 am SPEAKERS Joseph Pearlberg, MD, Vice President Clinical Development, Infinity Pharmaceuticals, Inc. New discoveries are finding links that extend significantly beyond the gut microbiome and intestinal disorders into a range Jerome Zeldis, MD, PhD, Chief Medical Officer of bodily systems including the immune and nervous systems. and President of Clinical Development, Sorrento Major biopharma companies have engaged in significant deals Therapeutics that envision treatments to commercialize from this research and leading companies are pushing forward on clinical trials. NEXT GENERATION PAIN CONTROL: This session will outline the microbiome influenced therapies BEYOND OPIOIDS most likely to create major effects for patients. Monday • February 13, 2017 • 1:30 pm – 2:25 pm MODERATOR: C. Simone Fishburn, PhD, Editor, The scourge of rising addiction and heroin overdoses has BioCentury Innovations been associated with the growth in usage of important, opioid- SPEAKERS Pierre Belichard, PharmD, PhD, Chief based, prescription pain treatments. New approaches to pain Executive Officer, Enterome control are looking at different biological mechanisms and Mark Bodmer, PhD, Chief Scientific Officer, methodologies for improving patients’ lives with lower risks Evelo Biosciences of ill effects or addiction. This session will speak with experts developing therapeutic innovations that do not rely on opioid- Board of Directors, Nick Conley, PhD, based drugs and can provide doctors additional alternatives for Co-founder & Chief Executive Officer, EpiBiome helping patients. JC Gutiérrez-Ramos, PhD, Chief Executive Officer, Synlogic MODERATOR: Corey Davis, PhD, Managing Director, Senior Jeffrey Riley, Chief Executive Officer, President Healthcare Analyst, H.C. Wainwright & Co., LLC and Director, Synthetic Biologics SPEAKERS Gail Cawkwell, MD, Chief Medical Officer, Nancy Thornberry, Chief Executive Officer, Purdue Pharma L.P. Kallyope (invited) Derek Chalmers, PhD, DSc, Chief Executive Nikola Trbovic, PhD, Director R&D Technology Officer, President, and Director, Cara Therapeutics Strategy, Worldwide Research & Development, Russell Herndon, President and Chief Pfizer Inc. Executive Officer, Hydra Biosciences Jeffrey B. Kindler, Chief Executive Officer, Centrexion Therapeutics FIRESIDE CHAT WITH J. JOSEPH KIM, PHD President and Chief Executive Officer, Gerhard Koenig, PhD, Chief Executive Officer, Inovio Pharmaceuticals Quartet Medicine, Inc. Monday • February 13, 2017 • 10:00 am – 10:55 am MODERATOR Phyllis A. Arthur, Managing Director, FIRESIDE CHAT WITH TONY COLES, MD Infectious Diseases and Diagnostics Policy, Biotechnology Chairman and Chief Executive Officer, Yumanity Therapeutics Innovation Organization Monday • February 13, 2017 • 2:30 pm – 3:25 pm MODERATOR Ian Woo, Managing Director, CAR-T, TILS, AND BISPECIFICS: IMMUNO- ONCOLOGY CHALLENGES AND OPPORTUNITIES Monday • February 13, 2017 • 11:00 am – 11:55 am IPOS AND BEYOND: TAPPING INTO THE PUBLIC The maturation of new cancer treatment technologies has MARKET’S CAPITAL produced a mix of highly positive patient outcomes and some Monday • February 13, 2017 • 3:30 pm – 4:25 pm serious clinical holds, while investments for manufacturing and As biotech IPO activity has cooled from its 2015 peak, commercialization continue to accelerate. This session will dive companies are more deliberately weighing reverse mergers into the assumptions underlying the most aggressive approaches and other alternatives to benefiting from the capital in public and the ways of reducing the risks of failure along the way to markets. With post-election market uncertainty, does the IPO delivering immuno-oncology’s promise to patients broadly. market for 2017 seek to rise, fall, or stay level? What markers should CEOs watch for to gauge their timing and choices? *Speakers added daily 4 bio.org/CEO CEO INVESTOR CONFERENCE

This session will feature experienced voices for explaining the EMBEDDING DIVERSITY INTO BOARD AND practical techniques for getting into public markets and what EXECUTIVE TEAM RECRUITMENT investors are expecting to see in order to win their support. Tuesday • February 14, 2017 • 10:00 am – 10:55 am MODERATOR Stephen B. Thau, Partner, Morrison & The biopharma industry has seen enormous growth in recent Foerster LLP years of the number of start-ups and IPOs, with hundreds of SPEAKERS James Cappuccio, Managing Director, new executive team and board member positions being filled. , H.C. Wainwright & Co., LLC However, the inclusion of underrepresented groups in these Brian Hagerty, Senior Director, Head of influential positions has failed to keep pace with the growth of Healthcare Capital Markets, New York biopharma companies and too often the decision-makers fail Stock Exchange to reflect the employee bases they lead or patient populations Douglas E. Onsi, Chief Financial Officer, they serve. This session will focus on practical approaches and Leap Therapeutics, Inc. successful examples to improve the diversity of leadership recruitment efforts and better align organizations with the full Sapna Srivastava, PhD, former Chief Financial measure of talented people available. Officer and Chief Strategy Officer, Intellia Therapeutics MODERATOR Julie L. Gerberding, MD, MPH, Executive Vice Nassim Usman, PhD, President and Chief President & Chief Patient Officer, Strategic Executive Officer, Catalyst Biosciences Communications, Global Public Policy and Population Health, Merck SPEAKERS Colleen Cuffaro, PhD, Principal, Canaan FIRESIDE CHAT WITH LYNN SEELY, MD President and Chief Executive Officer, Myovant Sciences Partners Paul J. Hastings, Chairman and Chief Executive Monday • February 13, 2017 • 4:30 pm – 5:25 pm Officer, OncoMed Pharmaceuticals MODERATOR K.C. Stone, Managing Director, Head of Dawn Hocevar, President, Women in Bio Healthcare Investment Banking, BTIG Stephen M. Ritoch, Chairman of the Board and Chief Executive Officer, Blaise Group LIVING WITH BIOSIMILARS: STRATEGY FORMULATION AND LESSONS FROM FIRESIDE CHAT WITH JEFFREY D. MARRAZZO, OTHER MARKETS Co-Founder and Chief Executive Officer, Spark Therapeutics Tuesday • February 14, 2017 • 9:00 am – 9:55 am Tuesday • February 14, 2017 • 12:00 pm – 12:55 pm As biosimilar medicine options begin to roll-out in the United States, the regulatory and legal uncertainties are also starting MODERATOR Erin McCallister, Senior Editor, BioCentury to shrink below the market adoption uncertainties. As some Publications innovator companies also pursue biosimilar development, and others seek to compete, there are opportunities to learn from jurisdictions that have allowed biosimilar medicines for longer POLICY OUTLOOK—ACA, CMS, PDUFA VI AND periods, such as Japan and Europe regarding the reactions THE TRUMP ADMINISTRATION of doctors and payers. This session will feature executives Tuesday • February 14, 2017 • 12:30 pm – 1:25 pm from innovator companies explaining how they evaluate biosimilars within their pipelines, plus those with expertise on From a healthcare policy point of view, 2017 has the potential understanding the economic effects seen when biosimilars of being the most dramatic since the initial introduction of launch within a market. the Affordable Care Act. The new Trump Administration has suggested an interest in making wholesale changes in how MODERATOR Elizabeth Krutoholow, Senior Analyst, medicines are regulated and paid for by the U.S. government. Bloomberg Intelligence PDUFA will expire later this year if its planned replacement is not SPEAKERS Jennifer Alltoft, Head of Global Biosimilars, passed in a timely fashion, greatly complicating companies’ drug Pfizer, Inc. development strategies and budgets. This session will share Patrick K. Lucy, Interim Chief Executive Officer, the latest details on what policies the Trump Administration Pfenex and Congress are pursuing that would support or upend the assumptions that biopharma executives and investors have built into their financial models.

*Speakers added daily

#BIOCEO17 5 MODERATOR Susan Peschin, MHS, President and Chief SPEAKERS Jeff Allen, PhD, President & Chief Executive Executive Officer, Alliance for Aging Research Officer, Friends of Cancer Research SPEAKERS Alex M. Azar II, Chairman, Seraphim Strategies, Gregory W. Daniel, PhD, MPH, RPh, Deputy LLC; former President, Lilly USA, LLC Director, Duke-Margolis Center for Health Policy (2012-2017); former Deputy Secretary, U.S. Steven Kaminsky, PhD, Chief Science Officer, Department of Health and Human Services Rettsyndrome.org (2005-2007) Christopher U. Missling, PhD, President and Cartier Esham, PhD, Executive Vice President Chief Executive Officer, Anavex Life Sciences for Emerging Companies, BIO Corp. Jonathan Leff, Partner, Deerfield Management; Raghuram Selvaraju, PhD, Managing Director, Chairman, Deerfield Institute Senior Healthcare Analyst, Rodman & Renshaw, Brian Rye, Senior Healthcare Policy Analyst, a unit of H.C. Wainwright & Co., LLC Bloomberg Intelligence FIRESIDE CHAT WITH GIOVANNI CAFORIO, MD CRAFTING NEW APPROACHES TO VALUE- Chief Executive Officer, Bristol-Myers Squibb BASED THERAPY PAYMENT MODELS: STARTING WITH GENE THERAPIES Tuesday • February 14, 2017 • 3:30 pm – 4:25 pm MODERATOR Stephen Sands, Vice Chairman Investment Tuesday • February 14, 2017 • 1:30 pm – 2:25 pm Banking and Chairman Global Healthcare Both innovator companies and payers of medicines have Group, Lazard expressed a willingness to look beyond the “fee per pill” model to attributing value to the effects on patients’ health instead. The challenge of reimbursing for curative therapies MARKET OUTLOOK—POST-INAUGURATION versus lifelong treatments of chronic conditions presents a SCENARIOS FOR M&A special challenge, but one that may shine a light on value- Tuesday • February 14, 2017 • 4:30 pm – 5:30 pm based approaches generally. This session will explore with the innovators making progress on gene therapies how they While the past year has seen a fading in the IPO market, the are envisioning the reimbursement model in ways that all volume of deal flow and valuations for M&A remain high. Many stakeholders might appreciate, including doctors’, patients’, and of the largest industry members have strong cash positions, payers’ perspectives. and most analysts continue to expect pipeline enhancement via acquisition. As political forecasts suggest high potential for tax MODERATOR Ted Haack, Owner, Managing Partner, reform and other changes in how international deals might be Haack & Associates reviewed, there are multiple ways 2017 could be a great year or a SPEAKERS John Glasspool, (formerly Executive Vice terrible year for biopharma M&A. This session will talk through the President, Head of Corporate Strategy and likely and extreme scenarios, as well as provide insight on what Customer Operations at Baxalta US, Shire) signs to watch for from Washington and Wall St. along the way. Sandy Macrae, MB, ChB, PhD, President and MODERATOR Asthika Goonewardene, Senior Biotech Chief Executive Officer, Sangamo Analyst, Bloomberg Intelligence Biosciences, Inc. SPEAKERS Adam H. Golden, Partner, Head of Corporate DESIGNING CLINICAL TRIALS IN A 21ST Practice Group—New York, Hogan Lovells CENTURY CURES PARADIGM Asthika Goonewardene, Senior Biotech Analyst, Bloomberg Intelligence Tuesday • February 14, 2017 • 2:30 pm – 3:25 pm Ellen Lubman, Vice President, External Science The passage by Congress of the 21st Century Cures Act in late & Innovation, Allergan PLC 2016 has opened up new opportunities and expectations for the Michael A. Margolis, RPh, Head of Healthcare design of clinical trials that the FDA will consider for regulatory Investment Banking, ROTH Capital Partners review. Real world evidence and the stronger inclusion of patient perspectives on endpoints are two examples of the Dennis J. Purcell, Founder and Senior Advisor, shifts that will impact therapy development. This session Aisling Capital will explain the advantages and complications that drug  Matthew Roden, PhD, Vice President and developers and investors should be aware of as the Cures Act Head of Strategic Corporate Development, gets implemented. Bristol-Myers Squibb MODERATOR Wade Ackerman, Partner, Covington & Burling LLP CLOSING RECEPTION AND CHAMPAGNE TOAST Tuesday • February 14, 2017 • 5:30 pm – 6:30 pm *Speakers added daily 6 bio.org/CEO CEO INVESTOR CONFERENCE

2017 PRESENTING COMPANIES* The 2017 BIO CEO & Investor Conference will better accommodate the growing diversity of investors and companies. While the majority of presenting companies at this event are publicly traded, with about half trading with market capitalizations above $100M, this meeting will once again feature a unique track of more than 30 high-caliber and established private company presentations.

CARDIOVASCULAR Caladrius Biosciences, Inc. Abpro Corporation WILEX AG (FWB: WL6) Angionetics Inc. (NASDAQ: CLBS) Actinium Pharmaceuticals, Inc Zenith Epigenetics Ltd. Espero Pharmaceuticals, Inc. Cellular Biomedicine Group (NYSE MKT: ATNM) OPTHALMOLOGY Karos Pharmaceuticals (NASDAQ: CBMG) AETERNA ZENTARIS (NASDAQ: AEZS) Inotek Pharmaceuticals Corporation Mast Therapeutics, Inc. Editas Medicine (NASDAQ: EDIT) Apexian Pharmaceuticals (NASDAQ: ITEK) (NYSE MKT: MSTX) Heat Biologics (NASDAQ: HTBX) Aveo Oncology (NASDAQ: AVEO) Ocugen, Inc. Resverlogix Corp. (TSX: RVX) LogicBio Therapeutics Inc BioLineRx Ltd. (NASDAQ, TASE: BLRX) ThromboGenics NV (Euronext: THR.BR) CNS/NEUROLOGICAL MaxCyte, Inc. (LSE: MXCT) Bio-Path Holdings, Inc. Oxford BioMedica (UK) Ltd (LSE: OXB) (NASDAQ: BPTH) ORPHAN/RARE DISEASE AcelRx Pharmaceuticals Akari Therapeutics Plc (NASDAQ: ACRX) TxCell SA (Euronext: TXCL.PA) Calithera Biosciences (NASDAQ: CALA) (NASDAQ: AKTX) Alcobra (NASDAQ: ADHD) IMMUNOLOGY Albireo Pharma Inc (NASDAQ: ALBO) Anavex Life Sciences Corp. BioNTech AG Cellectar Biosciences, Inc. (NASDAQ: CLRB) Arcturus Therapeutics (NASDAQ: AVXL) Enterome Bellerophon Therapeutics Axsome Therapeutics, Inc. OSE IMMUNOTHERAPEUTICS ConcentRx, Inc. CTI BioPharma Corp. (NASDAQ: CTIC) (NASDAQ: BLPH) (NASDAQ: AXSM) (Euronext: OSE) Eiger BioPharmaceuticals, Inc Bionomics Ltd (ASX: BNO, Sorrento Therapeutics (NASDAQ: SRNE) Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, CYCCP) (NASDAQ: EIGR) OTCQX: BNOEF) INFECTIOUS DISEASES EryDel SpA InVivo Therapeutics Corporation CytRx Corporation (NASDAQ: CYTR) Altimmune, Inc. Deepath Medical Diagnostics, Inc. KaloBios Pharmaceuticals, Inc. (NASDAQ: NVIV) AmpliPhi Biosciences Corp (NYSE (OTC: KBIO) NeuroRx, Inc. epiSCI MKT: APHB) Galena Biopharma, Inc. PhaseRx, Inc. (NASDAQ: PZRX) Neuralstem, Inc. (NASDAQ: CUR) ContraVir Pharmaceuticals, Inc. ProMetic Life Sciences (TSX: PLI) Neurotrope Bioscience (OTC: NTRP) Fennec Pharmaceuticals (TSX: FRX) (NASDAQ: CTRV) (NASDAQ: GALE) Spotlight Innovation Inc. PAION AG (FWB: PA8) EnBiotix, Inc (OTCQB: STLT) Probiodrug AG (Euronext: PBD) Gradalis, Inc. EpiBiome Gritstone Oncology, Inc Summit Therapeutics RaNA Therapeutics Microbion Corporation (NASDAQ: SMMT) Serina Therapeutics, Inc. HELIX BIOPHARMA CORP. (TSX: HBP) Rebiotix, Inc. IMMUNICUM AB (NASDAQ First North OTHER DERMATOLOGY Spring Pharmaceuticals, Inc. Premier: IMMU) 22nd Century (NYSE: XXII) Exicure Inc. (NASDAQ: SBPH) ImmunoCellular Therapeutics Ltd Akebia Therapeutics, Inc. Foamix Pharmaceuticals Vical Incorporated (NASDAQ: VICL) (NYSE: IMUC) (NASDAQ: AKBA) (NASDAQ: FOMX) INFLAMMATION Immunovaccine (TSX: IMV, Capnia, Inc. (NASDAQ: CAPN) Realm Therapeutics, Inc. (AIM: RLM) Noveome Biotherapeutics OTCQX: IMMVF) Science Exchange Sonoma Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc. (NASDAQ: SNOA) MEDICAL DEVICES PAIN MANAGEMENT Arch Therapeutics, Inc. (OTC: ARTH) (NASDAQ: INFI) Centrexion Therapeutics, Corp. DIAGNOSTICS CytoSorbents (NASDAQ: CTSO) iTeos Therapeutics SA Fortress Biotech, Inc. (NASDAQ: FBIO) Baebies, Inc. ProLung MabVax Therapeutics Holdings, Inc. KemPharm, Inc. (NASDAQ: KMPH) Chembio Diagnostics, Inc. Quandary Medical LLC dba TranS1 (NASDAQ: MBVX) Proove Biosciences Inc. (NASDAQ: CEMI) Mateon Therapeutics METABOLIC DISEASE Relmada Therapeutics, Inc. Curetis N.V. (Euronext: CURE) (OTCMKTS: MATN) (OTCQB: RLMD) Exactus, Inc. (OTCQB: EXDI) CohBar, Inc. (OTC: CBWR) MetaStat, Inc. (OTCBB: MTST) Exosome Diagnostics, Inc. Cymabay Therapeutics NERx Biosciences PLATFORM FOR THERAPEUTICS Invitae Corporation (NYSE: NVTA) (NASDAQ: CBAY) Novocure Limited (NASDAQ: NVCR) Dimerix Ltd (ASX: DXB) ITUS Corporation (NASDAQ: ITUS) Madrigal Pharmaceuticals, Inc. OncoMed Pharmaceuticals, Inc. Eligo Bioscience LexaGene Holdings Inc. (TSX: LXG.V) (NASDAQ: MDGL) (NASDAQ: OMED) RXi Pharmaceuticals Corporation OncoCyte (NYSE MKT: OCX) Orexigen Therapeutics, Inc. Onconova Therapeutics, Inc. (NASDAQ: RXII) (NASDAQ: OREX) (NASDAQ: ONTX) REGENERATIVE MEDICINE DRUG DELIVERY Synlogic Corium International, Inc. OncoSec Medical Incorporated BioTime, Inc. (NYSE MKT: BTX) Viking Therapeutics, Inc. (NASDAQ: ONCS) (NASDAQ: CORI) (NASDAQ: VKTX) REPRODUCTIVE/SEXUAL HEALTH NanoValent Pharmaceuticals Inc. Opsona Therapeutics Ltd. Agile Therapeutics, Inc (NASDAQ: AGRX) Oramed Pharmaceuticals MULTILINE GLOBAL BIOPHARMA Pieris Pharmaceuticals (NASDAQ: PIRS) Palatin Technologies, Inc. (NASDAQ: ORMP) NOIGEL, LLC Progenics Pharmaceuticals,Inc. (NYSE MKT: PTN) MULTIPLE THERAPEUTICS (NASDAQ: PGNX) GASTROINTESTINAL Salarius Pharmaceuticals RESPIRATORY Arena Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc. Aradigm Corporation (NASDAQ: ARDM) (OTCQB: CTXR) Scancell Holdings plc (LSE: SCLP.L) (NASDAQ: ARNA) SciClone Pharmaceuticals Inc GlaxoSmithKline, LLC (NYSE: GSK) Atlantic Healthcare plc Colby Pharmaceutical Company RespireRx Pharmaceuticals Inc. Mount Tam Biotechnologies (NASDAQ: SCLN) Conatus Pharmaceuticals Inc. Sierra Oncology (NASDAQ: SRRA) (OTCQB: RSPI) (NASDAQ: CNAT) (OTC: MNTM) Symic Bio, Inc. Sunesis Pharmaceuticals TOOLS/DRUG DEVELOPMENT Drais Pharmaceuticals, Inc (NASDAQ: SNSS) SUPPORT TECHNOLOGY Galectin Therapeutics TiGenix NV (Euronext: TIG) Valin Technologies Ltd Sutro Biopharma Inc. IonField Holdings LLC, (NASDAQ: GALT) Syndax Pharmaceuticals, Inc. dba IonField Systems RedHill Biopharma Ltd. NON-PROFIT/ADVOCACY (NASDAQ: SNDX) Vium Inc. (NASDAQ, TASE: RDHL) ORGANIZATION Syros Pharmaceuticals (NASDAQ: SYRS) Sigmoid Pharma Limited Jeffrey Modell Foundation VACCINES Tarveda Therapeutics JN Medical Corp. Synthetic Biologics, Inc (NYSE: SYN) Muscular Dystrophy Association TG Therapeutics (NASDAQ: TGTX) Tourette Association of America, Inc. Universal Stabilization Technologies, Inc. GENE/CEN THERAPY The Leukemia & Lymphoma Society Vaxess Technologies Argos Therapeutics, Inc (NASDAQ: ARGS) ONCOLOGY Vascular Biogenics LTD (NASDAQ: VBLT) Brainstorm cell Therapeutics 2X Oncology, Inc Vaxil Bio Ltd. (TSX-V: VXL) (NASDAQ: BCLI) 4SC AG (FWB: VSC) Verastem, Inc. (NASDAQ: VSTM) *List accurate as of 2/2/17

#BIOCEO17 7 2017 PARTICIPATING INVESTORS* INVESTOR INVESTORS First Island Capital NEA 5AM Ventures Fletcher Spaght Ventures Needham & Co. REGISTRATION A C Binder Corp Fountain Healthcare Partners Nexus LSP AbbVie Inc. F-Prime Capital Partners NJ Investment Division Aceras Franklin Templeton Noble Equity UP MORE THAN Aceras Life Sciences FundRx NOBLE Life Science Partners Aceras Partners GC Finance Nomura Instinet Acuris Partners GenScript International Aegis Capital Global Asset Advisors Nordcon Capital Aisling Capital LLC Good Health Capital Norgine Ventures Gradus/RSJ Life Sciences NovaQuest Capital 30% Akemi Capital ALEPH CAPITAL Griffin Securities Novatio Ventures Alignment Ventures, LLC H.C. Wainwright & Co. Novo Nordisk OVER 2016. Amzak Health HealthCare Royalty Partners NSIP LLC Arch Venture Partners Helix Management, Inc NYS Innovation Venture Capital Fund Ariel Investments Hercules Capital Oak Ridge Investments LLC Asahi Kasei America, Inc. Horizon Technology Finance Oberland Capital Horton Point LLC Oechsle International Advisors Ashford Capital Management Syno Capital Aspire Capital Partners Hudson Bay Capital Olayan America Corp Illumina Ventures Opaleye TaiAn Technologies/Eminent VC Astellas Venture Management LLC Tang Capital Management Athena Bio Ventures Innoviva, Inc. Opus Point Partners International Finance Corporation OrbiMed The Astrologers Fund, Inc Atheneos Capital TriPoint Global Equities Atlantic Capital Group Inventis Investment Holdings (China) Ltd Orchard View Capital Advisors LP iNVENTRAM INC. Oxford Finance TS Family of Funds Atlas Venture Turret Capital Mangement Capital IRC Securities/Strategy Signal Palo Alto Investors Iron Wolf Advisors Pappas Ventures V2M Capital Barclays Valquest Capital Management Barracuda Finance LLC Janney Montgomery Scott PARK AVE CAPITAL MGMT INTL. Jina Ventures Inc. Park York LLC Vector Resource Funds BioMed Ventures Versant Ventures Biondo Investment Advisors JMP Securities Peter B. Cannell & Co. Johnson & Johnson Innovation - JJDC Inc Petrus Capital Holdings Viriathus Holdings LLX Biotech Investment Group Virtus Inspire Ventures BioVenture Partners Johnston Associates Pfizer Inc JonesTrading Pipeline Capital WallachBeth Capital Bishop Capital Management WBB Securities LLC BMO Capital JP Morgan Securities Piper Jaffray Kalka Fund Prevail Partners LLC Wellington Financial BridegBio WestPark Capital BTIG Katz Associates Princeton BioPharma Capital Partners, LLC KESA Partners Prism Biomedical Research William Blair CAM Capital Wolf Capital Management Canaccord Genuity Ladenburg Thalmann & Co. QVT Financial Laidlaw & Company Raymond James Wolfswood Partners Capital Family Office Xeraya Capital Cato BioVentures LF Advisors LLC RBC Capital Markets Cedrus Investments LifeScience EquityPartners, LLC Relativity Healthcare Partners RESEARCH Chardan Capital Markets LifeTech Capital Ridgeback Capital Management Crede Capital Group Lincoln Park Capital Roosevelt Investments ANALYSTS Crown Point Group Little gem life sciences fund ROTH Capital Partners Bank of America/ Lynch Dabar Investment Associates Livingston LLC S&P Capital IQ Barclays Daniloff Capital Loeb Partners Sachs Investment Group Brean Capital Data Collective Loncar Investments Santen Inc Cantor Fitzgerald Deca Ventures, LLC Longitude Capital SBIC Program Chardan Capital Markets Deerfield Management LSWORKS Schroder Investment Management Cowen Delwar Capital Management LLC Madison Square Capital LLC Second Line Capital FBR & Co. Discover Fund Magid Family Office Serrado Capital Griffin Securities Domain Associates Magna Silicon Valley Bank H.C. Wainwright Dynamk Capital Marathon Asset Management Silverarc Capital, LLC JMP E Squared Capital Maxim Silverarrowpartners Ladenburg Thalmann Easton Capital Medex Capital SimRx advisors Laidlaw & Company Edgewood Management LLC Mediqventures Sio Capital Management Leerink EGB Advisors PR LLC Merck Skolkovo Biofund Lifetech Capital Eleven Biotherapeutics Mid Atlantic Bio Angels Slater Technology Fund Maxim Group Emerald Advisers Milestone Capital Sofinnova Ventures Enso Ventures Morgan Stanley Solar Capital Partners Needham & Co. ESC Advisors Morgens, Waterfall, Vintiaidus & Com- Source Capital Group Noble Life Sciences Eversept Partners pany, Inc. Stadnyk and Partners Family Office Piper Jaffray excelyrate Capital Mossrock Capital, LLC Stanphyl Capital RBC Capital Markets Faridan Mount Sinai Investment Fund SternAegis Ventures ROTH Capital Partners FBR & Co. MP Healthcare Venture SunTrust Robinson Humphrey FC Capital Management MVM Life Science Partners Surveyor Capital (Citadel LLC) Source Capital MVP Capital Partners SV Life Sciences Managers LLP Sun Trust Humphrey Robinson *List accurate as of 2/2/17 Symphony Capital LLC WallachBeth

8 bio.org/CEO CEO INVESTOR CONFERENCE

BIO ONE-ON-ONE PARTNERING MEETINGS SCHEDULED MEETINGS UP 20% Using the system, companies are able to: BIO’s One-on-One Partnering™ m Pre-schedule 30-minute private 1x1 meetings system is the interactive m Source potential collaborations and funding environment that allows opportunities with an international audience you to increase your productivity, discover m Communicate directly with prospective new investment and investors and C-level executives in biotech licensing opportunities, and pharma and expand your business potential worldwide. m Search company and investor profiles for potential business partnerships

AUDIENCE DEMOGRAPHICS Job Profile: Attendees: 1,400+ 86% BIO One-on-One 86% of attendees Partnering Meetings: 2,500+ are VP or C-Level 86% Registered Investors: 650 4% 10% 76% 10% Company Presentations: 190 Other Director C-level VP Expert Speakers: 58

Companies Profile: Breakdown by Therapeutic Focus: Diagnostics: 2% Infectious Diseases: 2% 82% of all companies Gastrointestinal: 3% Platform Discovery: 2% attending are biopharma 82% Cardiovascular: 3%

Regenerative Medicine: 3% Oncology: 29% Multiple: 4%

Breakdown by Market Cap: Ophthalmology: 4% $250M-500M: 6% $500M: 4% Metabolic Diseases: 4%

Devices & Drug Delivery: 4% $50M-100M: 22% CNS: 13% < $50M: 36% Autoimmune Inflammation:7%

Orphan/Rare Diseases: 10% Other: 10% $100M-250M: 32%

#BIOCEO17 9 SPONSORS LOCAL CO-HOST REGIONAL PARTNERS

SUPPORTING BANK SPONSORS

DOUBLE HELIX SPONSORS HELIX SPONSOR

CONFERENCE SPONSORS

usedlabequipment.com

MEDIA PARTNERS

TM

10 10 bio.org/CEO CEO INVESTOR CONFERENCE

February 13-14, 2017 • The Waldorf Astoria New York ADVISORY COMMITTEE

John Chambers Barbara J. Dalton, PhD Linda S. Grais, MD Brian Hagerty Nouhad Husseini President and Head of Vice President, Venture President and Chief Senior Director, Head Vice President, Healthcare Investment Capital, Pfizer Inc. Executive Officer, Ocera of Healthcare Capital Business Development, Banking, H.C. Therapeutics, Inc. Markets, New York Regeneron Wainwright & Co. LLC Stock Exchange Pharmaceuticals, Inc.

Mike King Jonathan Leff Michael Margolis, RPh Michael Mirsky Timothy P. O’Connor, PhD Managing Director and Partner, Deerfield Managing Director and Managing Director, Executive Vice President, Senior Biotech Analyst, Management; Head of Healthcare Investment Banking, The Rockefeller University JMP Securities Chairman, Deerfield Investment Banking, H.C. Wainwright & Co., LLC Institute ROTH Capital Partners

Jason Park Susan Peschin, MHS Dennis J. Purcell Carlo Rizzuto, PhD Matthew Roden, PhD Principal, Flagship President and CEO, Founder and Senior Partner, Versant Vice President and Head Ventures Alliance for Aging Advisor, Aisling Capital Ventures of Strategic Corporate Research Development, Bristol- Myers Squibb

Stephen Sands Rajeev Shah Nathan Tinker, PhD Vice Chairman Investment Managing Director and Executive Director, Banking and Chairman Portfolio Manager, New York BIO Global Healthcare Group, RA Capital Management Lazard

#BIOCEO17 11 COMPLIMENTARY RESERVE YOUR SPOT TODAY! REGISTRATION IS AVAILABLE TO BIO offers a number of ways for conference QUALIFIED INVESTORS* attendees to save money on their registration fees. * Defined as institutional, private equity, angel Group pricing available when registering and venture investors with funds on-hand, whose primary activity is direct investment in three or more employees. If your company is research and development companies (e.g., registering more than three employees, please hedge fund, mutual fund, or venture fund). Equity research analysts from investment contact BIO at mailto:[email protected] for banking institutions and buy-side analysts further discounts. also qualify as investors. The fund name, portfolio type, or other Discounted packages for presenting helpful information is needed for BIO to companies and organizations bringing three or process your registration appropriately. Receipt of complimentary registration for more attendees. a prior year’s event does not automatically Special rates for academics, non-profits, qualify a registrant for complimentary registration in 2017. government, service providers and suppliers.

Go to bio.org/ceo and register now!

1 All eligible biotech and pharma companies REGISTRATION FEES BIO Member Rate Standard Rate receive up to a 10% discount when registering three employees. If your company is registering Biotech/Pharma Company $2,000 $2,500 more than three employees, please contact BIO for further discounts. Please note: The group package rate does NOT include a corporate Group Package1 $5,400 $6,750 presentation. 2 A code is required to register as a presenter for Academic/Gov’t/Non-Profit3 $875 $875 a company presentation. If you have already been confirmed as a presenter, you should have Service Providers/Suppliers $4,000 $5,000 received a registration code with a checklist. If you are interested in presenting, please contact Brian Pinkston at [email protected]. PRESENTATION FEES BIO Member Rate Standard Rate 3 A code is required for academic, government, and non-profit registration. Please send your Public Company 1/2 $3,000 $3,750 request to [email protected].

Private Company 1/2 $2,000 $2,500

VENUE The Waldorf Astoria New York JOIN THE CONVERSATION: 301 Park Avenue New York, NY 10022 Learn more about Biotechnology at bio.org phone: 212.355.3000 Engage with the Biotech Community at BIOtech-NOW.org A limited number of rooms are available at the Follow us on Twitter @bio1x1 or #BIOCEO17 BIO discounted rate. Please make your reservations directly with the hotel. Become a fan on Facebook (facebook.com/IAmBiotech)

12 bio.org/CEO HOSTED BY: